EUVIMEDEUVIMED entdecken
EditorialKommentar

JZP458 closes the asparaginase allergy gap

Josep-Maria Ribera iD

Blood · 2023

DOI: 10.1182/blood.2022018395 ↗

Kurz gefasst

Editorial in der Zeitschrift Blood, 2023. Verfasst von Josep-Maria Ribera. Beteiligte Einrichtung: Josep Carreras Research Institute. Hauptthemen laut MEDLINE: Antineoplastic Agents, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Drug Hypersensitivity, Erwinia. Die Arbeit nennt 9 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this issue of Blood, Maese et al 1 showed that intramuscular (IM) JZP458 at 25/25/50 mg/m 2 given thrice weekly was an effective and safe alternative for patients with hypersensitivity to Escherichia coli-derived asparaginases (ASPs).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsPrecursor Cell Lymphoblastic Leukemia-LymphomaDrug HypersensitivityErwiniaHypersensitivityHumansAsparaginase

Substanzen

AsparaginaseAntineoplastic Agents

Autor:innen und Institutionen

  • Josep Carreras Research Institute.

ORCID-Profile: Josep-Maria Ribera

Zitieren

APA

Ribera, J. M. (2023). JZP458 closes the asparaginase allergy gap. Blood. https://doi.org/10.1182/blood.2022018395

Vancouver

Ribera JM. JZP458 closes the asparaginase allergy gap. Blood. 2023. doi:10.1182/blood.2022018395

BibTeX
@article{Ribera2023,
  author = {Ribera, Josep-Maria},
  title = {JZP458 closes the asparaginase allergy gap},
  journal = {Blood},
  year = {2023},
  doi = {10.1182/blood.2022018395}
}
Kostenlos starten →